Cargando…
In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia
Recent studies suggest that treatment with SGLT-2 inhibitors can reduce hepatic lipid storage and ameliorate non-alcoholic fatty liver disease (NAFLD) development beyond their glycemic benefits. However, the exact mechanism involved is still unclear. We investigated the hepatic metabolic effect of e...
Autores principales: | Hüttl, Martina, Markova, Irena, Miklankova, Denisa, Zapletalova, Iveta, Poruba, Martin, Haluzik, Martin, Vaněčkova, Ivana, Malinska, Hana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584090/ https://www.ncbi.nlm.nih.gov/pubmed/34768942 http://dx.doi.org/10.3390/ijms222111513 |
Ejemplares similares
-
Metformin Affects Cardiac Arachidonic Acid Metabolism and Cardiac Lipid Metabolite Storage in a Prediabetic Rat Model
por: Miklankova, Denisa, et al.
Publicado: (2021) -
Ovariectomy-Induced Hepatic Lipid and Cytochrome P450 Dysmetabolism Precedes Serum Dyslipidemia
por: Malinská, Hana, et al.
Publicado: (2021) -
The Beneficial Additive Effect of Silymarin in Metformin Therapy of Liver Steatosis in a Pre-Diabetic Model
por: Hüttl, Martina, et al.
Publicado: (2021) -
Hypolipidemic and insulin sensitizing effects of salsalate beyond suppressing inflammation in a prediabetic rat model
por: Hüttl, Martina, et al.
Publicado: (2023) -
The Different Insulin-Sensitising and Anti-Inflammatory Effects of Palmitoleic Acid and Oleic Acid in a Prediabetes Model
por: Miklankova, Denisa, et al.
Publicado: (2022)